Please assess the completion status of the following clinical trial:

Trial Title: Bacillus Calmette-guérin Vaccination to Prevent Infections of the Elderly

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female~* Age more than or equal to 65 years based on the precise date of birth~* Discharge from hospital after hospitalization for a medical cause. All medical causes make patients eligible for enrolment with the only exception of medical causes mentioned in the exclusion criteria~Exclusion Criteria:~* Failure to obtain written informed consent~* Solid organ malignancy or lymphoma diagnosed the last five years~* Treatment with oral or intravenous steroids defined as daily doses of 10mg prednisone or equivalent for longer than 3 months~* Severely immunocompromised patients. This exclusion category comprises: a) patients with known infection by the human immunodeficiency virus (HIV-1); b) neutropenic patients with less than 500 neutrophils/mm3; c) patients with solid organ transplantation; d) patients with bone marrow transplantation; e) patients under chemotherapy; f) patients with primary immunodeficiency; g) severe lymphopenia with less than 400 lymphocytes/mm3; h) treatment with any anti-cytokine therapies~* Positive Interferon-gamma Release Assay (IGRA)

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): One intradermal injection of 0.1ml of sodium chloride 0.9%
- Vaccination (Type: ACTIVE_COMPARATOR): One intradermal injection of 0.1ml of BCG (BCG vaccine Bulgaria strain 1331; Intervax)

Based on this trial design, predict the completion outcome and termination type (if applicable).